AlgoTherapeutix is the operator of a biotechnology company designed to develop topical treatments for complex pain.
AlgoTx creates solutions to help patients suffering from difficult-to-treat conditions. The organization accomplishes this by emphasizing conditions with no proven or licensed therapy and adapting treatment to the very particular needs of the people afflicted. ATX01's admission into Phase 2 in Chemotherapy-Induced Peripheral Neuropathy has been approved by the FDA. In the meanwhile, AlgoTx is investigating its potential in erythromelalgia, a rare and painful condition.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 14, 2022 | Series B | €20M | — | — | — | Detail |
Nov 24, 2020 | Series A | $12M | 2 | Bpifrance | — | Detail |
Nov 20, 2019 | Seed | €2.60M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bpifrance | Yes | Series A |
Omnes Capital | — | Series A |